Is Dogwood Therapeutics, Inc. (DWTX) a Buy, Sell, or Hold?
NASDAQ : DWTX
Dogwood Therapeutics, Inc.
$1.37 USD
-$0.07 (-4.86%)
- Volume
- 55.88K
- Average Volume
- 110.27K
- Market Capitalization
- $2.62M
- P/E Ratio
- -0.13
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.50
- Year Low
- $1.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.86
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gregory Duncan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DWTX |
| CUSIP | 92829J203 |
| CIK | 0001818844 |
| Web | https://www.dwtx.com |
| Phone | 866 620 8655 |
| Currency | USD |
| Employees | 8 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.86 |
| Quick Ratio | 5.86 |
| Cash Ratio | 5.17 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.46 |
| Price / Cash Flow | -0.17 |
| Price / Book | 0.57 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$4.32 |
| Trailing P/E Ratio | -0.13 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | -$34.26M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -35.91% |
| Return on Assets | -29.74% |
Financials Score
| AltmanZ Score | -2.37 |
| Piotroski Score | 2.00 |
| Working Capital | 12.44M |
| Total Assets | 95.21M |
| Ebit | -28.29M |
| Market Cap | 2.73M |
| Total Liabilities | 14.58M |
Poll Results
About Dogwood Therapeutics, Inc. (NASDAQ:DWTX) Stock
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company main ... tains its main office in Alpharetta, Georgia.
2026-06-30 08:45:00
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-16 12:02:09
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
2026-05-18 08:45:00
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
2026-05-14 08:30:00
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
2026-05-07 08:30:00
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders.
2026-04-23 09:00:00
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood's anti-viral candidates, IMC-1 and IMC-2.
Frequently Asked Questions
-
What is the current Dogwood Therapeutics, Inc. (DWTX) stock price?
-
Dogwood Therapeutics, Inc.(NASDAQ:DWTX) stock price is $1.37 in the last trading session. During the trading session, DWTX stock reached the peak price of $9.5 while $1.28 was the lowest point it dropped to. The percentage change in DWTX stock occurred in the recent session was --4.86% while the dollar amount for the price change in DWTX stock was -$0.07.
-
DWTX's industry and sector of operation?
-
The NASDAQ listed DWTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DWTX?
-
R. Michael Gendreau | Chief Medical Officer
William L. Pridgen | Founder & Member of Scientific Advisory Board
Gregory Duncan | Chairman & Chief Executive Officer
Ralph D. Grosswald | Senior Vice President of Operations
Angela Walsh | Chief Financial Officer, Secretary & Treasurer -
How many employees does DWTX have?
-
Number of DWTX employees currently stands at 8. DWTX operates from 44 Milton Avenue, Alpharetta, GA 30009, US.
-
Link for DWTX official website?
-
Official Website of DWTX is: https://www.dwtx.com
-
How do I contact DWTX?
-
DWTX could be contacted at phone #866 620 8655 and can also be accessed through its website. DWTX operates from 44 Milton Avenue, Alpharetta, GA 30009, US.
-
How many shares of DWTX are traded daily?
-
The average number of DWTX shares traded daily for last 3 months was 110.27K.
-
What is the market cap of DWTX currently?
-
The market value of DWTX currently stands at $2.62M with its latest stock price at $1.37